TODAY'S HEADLINES

Diabetes drugs may be linked to heart failure, FDA warns

Popular type 2 diabetes drugs containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease, according to FDA's new Drug Safety Communication. Find out which drugs are affected. Read more

Biosimilar approvals deemed too slow

While FDA's approval of infliximab-dyyb (Inflectra, Celltrion), a biosimilar to Remicade for rheumatoid arthritis, Chron's disease and other conditions is positive, FDA's approval pace for biosimilars is too slow, according to a pharmacy benefit manager. Find out why

CONTINUING PHARMACY EDUCATION

The expanding role of direct oral anticoagulants in the management of thromboembolic disease

This month's CE activity is open for pharmacists and pharmacy technicians: "The expanding role of direct oral anticoagulants in the management of thromboembolic disease." Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

National diabetes program saves thousands

A YMCA diabetes prevention program has been so successful that the Obama administration is planning to offer it to all Medicare members in 2017. Read more

April 13, 2016

Related Articles

Major diabetes drug cuts heart attack risk

Biosimilars' savings could be lower than predicted